Site-related variance in MRI measures is generally small (typically <10%) in the AMP SCZ multi-site neuroimaging protocol, but platform-related variance is substantial for diffusion imaging SNR/CNR (>55%) and spatial smoothness.
In the AMP SCZ multi-site neuroimaging protocol, site-related variance is generally small (typically <10%) for most MRI measures. However, for diffusion-weighted imaging, platform-related variance accounts for >55% of the variance in signal-to-noise and contrast-to-noise ratios due to hardware differences, and spatial smoothness also shows large platform-related variance.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Site-related variance in MRI measures is generally small (typically <10%) in the AMP SCZ multi-site neuroimaging protocol, but platform-related variance is substantial for diffusion imaging SNR/CNR (>55%) and spatial smoothness. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Site-related variance in MRI measures is generally small (typically <10%) in the AMP SCZ multi-site neuroimaging protocol, but platform-related variance is substantial for diffusion imaging SNR/CNR (>55%) and spatial smoothness.
This conclusion is most relevant to: Individuals at clinical high risk (CHR) for developing psychosis in the Accelerating Medicines Partnership Schizophrenia Program (AMP SCZ)..
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program. (Schizophrenia (Heidelberg, Germany), 2026) —
How It Works
The proposed biological pathway:
- ▸Multi-site MRI data collected from different scanner models
- ▸Variance component analysis performed on SNR/CNR and spatial smoothness
- ▸Site-related variance found to be small (<10%) for most measures
- ▸Platform-related variance dominates for diffusion imaging (>55%) and spatial smoothness
Who Might Benefit
Evidence fit by population:
- ▸Individuals at clinical high risk (CHR) for developing psychosis in the Accelerating Medicines Partnership Schizophrenia Program (AMP SCZ).
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Preliminary variance component analyses only; full cohort results not yet available
- ▸Platform-related variance may limit generalizability of diffusion imaging findings across scanner types
References
- 1.Harms MP, Cho KK, Anticevic A, Bolo NR, Bouix S, Campbell D, Cannon TD, Cecchi G, Goncalves M, Haidar A, Hughes DE, Izyurov I, John O, Kapur T, Kim N, Kotler E, Kubicki M, Kuperman JM, Laulette K, Lindberg U, Markiewicz C, Ning L, Poldrack RA, Rathi Y, Romo PA, Tamayo Z, Wannan C, Wickham A, Yassin W, Zhou JH, Addington J, Alameda L, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Diaz-Caneja CM, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Mathalon DH, Mittal VA, Nordentoft M, Pearlson GD, Perez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Thompson JL, Upthegrove R, Verma SK, Wang J, Wolf DH, Kahn RS, Kane JM, McGorry PD, Nelson B, Woods SW, Shenton ME, Wood SJ, Bearden CE, Pasternak O. “The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program..” Schizophrenia (Heidelberg, Germany), 2026. PMID: 40175382 DOI: 10.1038/s41537-025-00581-6